

# SPHHP Research Activities Newsletter

University at Buffalo

March 2018

## In the News

### Congratulations to the Following Awardees!



**David Hostler**, Professor and Chair of Exercise and Nutrition Sciences, is PI on a continuation award from the Naval Seas System Command/U.S. Department of Defense, for the project entitled *Optimizing Performance during Topside Operations and Diving at Altitude*. The study is testing the hypothesis that voluntary isocapnic hyperpnoea training will improve exercise performance during acute exposure to a simulated altitude of 12,000 ft. **David Pendergast**, Professor Emeritus of Physiology and Biophysics and Exercise and Nutrition Sciences, is Co-Investigator.



**Katia Noyes**, Professor of Epidemiology and Environmental Health, is PI on a new award from the Benaroya Research Institute at Virginia Mason/NIAID/NIH for the project entitled *Immune Tolerance Network BEAT-MS*. The study is a multi-center, prospective, unblinded, randomized, controlled trial comparing the Best Available Approved Therapy (BAAT) strategy versus the Autologous Hematopoietic Stem Cell Transplant (AHSCT) treatment strategy for treatment-resistant relapsing-remitting multiple sclerosis.



**Christine Oddo**, Director of Client Services, Center for Assistive Technology, received a supplement from the New York State Justice Center for the Protection of People with Special Needs for the project entitled *TRAIID Supplemental Funding*. The funding will provide additional equipment for the TRAIID program, which supports the development of state-wide consumer-responsive technical assistance programs for persons with disabilities.



**Jerome Yates**, Clinical Professor of Epidemiology and Environmental Health, is PI on a renewal award from the P2 Collaborative of Western New York Inc. entitled, *Population Health Improvement Program*. The P2 Collaborative is coordinating efforts to improve health in the eight counties of Western New York. Dr. Yates will participate in the committee evaluating the available public health data and the Steering Committee for the organization. He also will work to keep stakeholders aware of the relevant activities in UB's Jacob School of Medicine and Biomedical Sciences and School of Public Health and Health Professions.



**Joshua Gordon**, MD/PhD student in the Medical Scientist Training Program, Dept. of Epidemiology and Environmental Health, received a continuation of his fellowship award from the National Heart, Lung, and Blood Institute/NIH for the project entitled *Epidemiologic Evaluation of Risk Factors for Hypertension in Postmenopausal Women: Periodontal Disease, the Oral Microbiome, and Systemic Inflammation*. The project will continue to examine whether the systemic inflammation associated with periodontal disease, edentulism (the complete absence of teeth), and the composition of the oral microbiome is associated with the risk of incident hypertension in postmenopausal women. **Jean Wactawski-Wende**, Dean of SPHHP and Professor of Epidemiology and Environmental Health, serves as faculty sponsor.

#### Inside this issue:

In the News	1
Grant Clinic	2-3
NIH Funding:	
Limited	3
RFA	3-6
PAS	7
PAR	7-8
PA	8-9
Foundations:	
Gates	9
Robert Wood Johnson	9
Words to Live By	9

# Grant Clinic

For those interested in trends in funding at NIH, we reprint a recent post from the NIH Office of Extramural Research.

## How Many Researchers, Revisited: A Look at Cumulative Investigator Funding Rates

Posted on March 7, 2018 by Mike Lauer

In May 2016, we posted a blog on “How Many Researchers” NIH supports. We cited the findings of a University of Wisconsin workshop, which concluded that the biomedical research enterprise suffers from two core problems: too many scientists vying for too few dollars and too many post-docs seeking too few faculty positions. We also noted that NIH leadership and others were increasingly interested in describing the agency’s portfolio not only in terms of the numbers of awards and dollars (as we do each year in our “By the Numbers” reports), but also in terms of the numbers of researchers those awards support. Today we show updated figures on how many researchers are vying for NIH support and how many are successful. [Continue Reading](#) -

## Sources Available to Search for Funding Opportunities

Looking for funding sources to support your research? In addition to the opportunities listed in the RAS monthly Newsletter, there are a number of search engines available and searches may be done by topic, mechanism, or funding source. Please contact the RAS staff if you have any questions or need assistance with your funding search.

- SPIN (Sponsored Programs Information Network): SPIN is an extensive database that allows researchers to search over 40,000 funding opportunities, including federal, public, non-profit, and private sponsors. If you have not already done so, you are encouraged to register a SPIN profile – this will allow you to save search preferences or sign up for email notifications. You must be currently affiliated with UB and have an active UB email address. To register, please visit <https://spin.infoedglobal.com>, click ‘Sign In’, in the top right corner and select ‘Need to Create a New Profile’.
- NIH Funding: If you are looking for opportunities within NIH, you can search by institute; key words; and/or activity codes. <https://grants.nih.gov/funding/searchGuide/>
- National Science Foundation (NSF): Begin your NSF funding search by visiting the [Research Areas](#) page, which offers a list of the seven directorates, as well as subdivisions. In addition to funding opportunities, each sub division’s page also offers contact information, news and division specific announcements. If you would like to search within all of NSF, you can browse current opportunities at <https://www.nsf.gov/funding/azindex.jsp>.
- Grants.Gov: Opportunities released by all federal agencies, such as the DOD, Dept. of Education, and Dept. of Veteran Affairs, are listed at: <https://www.grants.gov/web/grants/search-grants.html>. The filters allow a search to be done by agency, category, keywords, eligibility, and opportunity numbers.
- Catalog of Federal Domestic Assistance (CFDA): Another source of federal funding, the CFDA provides detailed descriptions for more than 2,300 federal assistance programs. <https://www.cfd.gov/>
- New York State Funding: New York State Grants Gateway is the primary outlet for stage agencies to post upcoming funding opportunities. [https://grantsgateway.ny.gov/IntelliGrants\\_NYSGG/module/nysgg/goportal.aspx](https://grantsgateway.ny.gov/IntelliGrants_NYSGG/module/nysgg/goportal.aspx). NYS offers [training webinars](#) for those unfamiliar with the Grants Gateway.
- UB Seed and Pilot Funding: In order to assist in strengthening grant applications, UB offers several seed funding opportunities, such as RENEW; Genome, Environment, and Microbiome; Community for Global Health Equity; IMPACT; and the OVPRED Grant Resubmission awards. Information on each program is located at <http://www.buffalo.edu/research/research-services/find-funding/find-ub-funding/current--annual-and-ongoing-funding.html>

## NIH Notices

### NOT-OD-18-149

#### **National Science Foundation - National Institutes of Health NSF-NIH Interagency Initiative: Smart and Connected Health**

The purpose of this solicitation is the development of technologies, analytics and models supporting next generation health and medical research through high-risk, high-reward advances in computer and information science, engineering and technology, behavior, cognition, robotics and imaging. Application submission is through the National Science Foundation via solicitation [NSF-18-541](#). Following a jointly conducted initial peer review of these applications, likely NIH awardees applications will be forwarded for NIH processing. Please refer to the NIH notice for the general interests of the participating NIH Institute organizations.

[NOT-OD-18-137](#)

### **Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2018**

Effective January 7, 2018, the NIH salary limitation for Executive Level II is \$189,600. For awards that are restricted to previous Executive Level II limits, if adequate funds are available in active awards, and if the salary cap increase is consistent with the institutional base salary, grantees may rebudget to accommodate the current Executive Level II salary level. However, no additional funds will be provided to these grant awards.

## **University at Buffalo Funding Opportunities**

### **Proteomics and Bioanalysis Core Seed Fund**

The OVPRED's office has announced the availability of internal funding to support new research initiatives that involve proteomic studies. The goal of this program is to stimulate new research directions and projects that foster the utilization of advanced proteomics technology and to develop preliminary data that can support external grant applications.

Awardees will be provided vouchers up to \$15,000 to the Proteomics and Bioanalysis Core that can only be used toward LC-MS charges and efforts of core personnel for sample preparation and basis data analysis. Supplies such as labeling reagents (where applicable), columns, traps, etc., and efforts on extended biological data interpretation are not included and must be provided by the awardee. Award recipients are required to submit a proposal for external funding within 18 months of the award start date. To apply, submit as a single pdf a 3 page page description of the project clearly showing that the proteomics aim will enhance the competitiveness of a planned external funding application. In addition, attach biosketches for the PI and other key personnel including current and pending funding. Applicants should discuss their projects with Proteomics Core Director, Professor Jun Qu @ [junqu@buffalo.edu](mailto:junqu@buffalo.edu) prior to submission.

**Application Due Date:** Applications will be accepted on a rolling basis until funds are exhausted. Email the pdf to Kenneth Tramosch, [ovpr.proteomics@research.buffalo.edu](mailto:ovpr.proteomics@research.buffalo.edu)

## **NIH Funding Opportunities: Limited Submissions**

UB prior approval is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. The limited submission program is managed by Dr. Kenneth Tramosch on behalf of the OVPRED. He may be contacted at [kmt1@buffalo.edu](mailto:kmt1@buffalo.edu) or by phone at 645-3321 for any questions or advice about the limited submission process.

[PAR-17-340 \(RM1\)](#) – (clinical trial not allowed)

### **Collaborative Program Grant for Multidisciplinary Teams**

This FOA is designed to support highly integrated research teams of three to six PD/Pis to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.

*Only one application per institution per review cycle is allowed.* **Application Due Dates:** May 7, 2018; September 7, 2018; May 7, 2019; September 7, 2019; May 7, 2020; September 7, 2020

[PAR-17-068 \(T34\)](#)

### **Maximizing Access to Research Careers Undergraduate – Student Training in Academic Research**

The Program is designed to provide structured training programs to prepare high-achieving, underrepresented students for doctoral programs in biomedical research fields. Programmatic activities should include authentic research experiences, academic enhancements, skills development, and mentoring. *Only one application per institution is allowed.* **Application Due Date:** May 24, 2018

## **NIH Funding Opportunities: Requests for Applications (RFA)**

### **May Due Dates**

[RFA-MD-18-005 \(R01\)](#) – clinical trial required

### **Youth Violence Prevention Interventions that Incorporate Racism/Discrimination Prevention**

This initiative supports research to develop and test youth violence prevention interventions that incorporate racism/discrimination prevention strategies for one or more health disparity populations. The target age range includes middle school to high school-aged youth, corresponding to an approximate age range of 11 to 18.

**Application Due Date:** May 28, 2018

## June Due Dates

[RFA-AG-19-001 \(P30\)](#) – clinical trial not allowed

### **Alzheimer's Disease Research Centers**

NIA-designated Alzheimer's Disease Research Centers serve as major sources of discovery into the nature of Alzheimer's disease and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators. **Application Due Date:** June 4, 2018

[RFA-ES-18-004 \(R35\)](#) – clinical trial not allowed

### **Revolutionizing Innovative, Visionary Environmental Health Research (RIVER)**

The RIVER program provides support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award. **Application Due Date:** June 20, 2018

[RFA-CA-18-019 \(R01\)](#); [RFA-CA-18-020 \(R21\)](#) – clinical trial optional

### **Research Answers to National Cancer Institute's (NCI) Provocative Questions**

The purpose of these FOAs is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. The current issuance of the PQ Initiative includes an updated set of 12 PQs, which can be found in the FOAs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list.

**Application Due Date:** June 29, 2018, October 30, 2018

[RFA-GM-18-002 \(R25\)](#) – clinical trial not allowed

### **Training Modules to Enhance the Rigor and Reproducibility of Biomedical Research**

This FOA will support creative educational activities with a primary focus on developing courses for skills development - specifically, exportable training modules designed to enhance the rigor and reproducibility of biomedical research, targeted to trainees and researchers at any level. **Application Due Date:** June 29, 2018

## July Due Dates

[RFA-DK-17-027 \(R01\)](#) – clinical trial required

### **Incorporating Patient-Reported Outcomes into Clinical Care for Type 1 Diabetes**

This FOA will support research to test approaches in the healthcare setting to using Patient-Reported Outcomes (PROs) as tools to enhance patient-centered treatment and improve outcomes in individuals with type 1 diabetes.

**Application Due Date:** July 10, 2018

[RFA-DK-17-028 \(R01\)](#) – clinical trial required

### **Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes**

This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with T1D and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life. **Application Due Date:** July 10, 2018

## August Due Dates

[RFA-CA-18-011 \(R44\)](#) – clinical trial optional

### **SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization**

This FOA solicits applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. **Application Due Date:** August 15, 2018

## November Due Dates

[RFA-DA-19-005 \(R61/R33\)](#) – clinical trial required

### **Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment**

This FOA solicits applications proposing phased research projects, with transition milestones, to develop and rigorously test the effects of strategies to improve opioid treatment quality measures, both on changes in the measures themselves and on patient outcomes. The overall goal is to advance the field of clinical quality measurement and management in opioid use disorder treatment by generating research better aligning quality measurement with quality improvement.

**Application Due Date:** November 7, 2018

## Multiple Due Dates

[RFA-DK-17-024 \(R01\)](#) – clinical trial required

### **Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D)**

This FOA encourages clinical trials testing the clinical efficacy of new technology to improve glucose control, reduce hypoglycemic events and/or improve quality of life in older T1D patients (aged 65 and older). Studies may utilize CGM technologies in open or closed loop systems with different degrees of automation {sensor/MDI, sensor augmented pumps with or without low glucose suspend (LGS), hybrid and fully automated systems}.

**Application Due Dates:** April 26, 2018; December 6, 2018

[RFA-CA-18-004 \(R21\)](#) – clinical trial not allowed

### **Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Application Due Dates:** May 29, 2018; September 28, 2018

[RFA-CA-18-005 \(R33\)](#) – clinical trial not allowed

### **Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. **Application Due Dates:** May 29, 2018; September 28, 2018

[RFA-MH-17-604 \(R61/R33\)](#) - **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

[RFA-MH-17-606 \(R33\)](#) - **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

The purpose of these FOAs is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. These FOAs support the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. **Application Due Dates:** June 15, 2018; October 15, 2018

[RFA-MH-17-612 \(R34\)](#)

### **Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions**

This FOA encourages pilot research consistent with [NIMH's priorities](#) for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. **Application Due Dates:** June 15, 2018, October 15, 2018

[RFA-MH-18-700 \(Collaborative R01\)](#) - clinical trial and participation of two or more collaborative sites required

[RFA-MH-18-701 \(R01\)](#) – clinical trial required

### **Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions**

These FOA support clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings.

**Application Due Dates:** June 15, 2018, October 15, 2018

[RFA-MH-18-702 \(R61/R33\)](#) – clinical trial required

[RFA-MH-18-703 \(R33\)](#) - clinical trial required

### **Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders**

These FOAs support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

**Application Due Dates:** June 15, 2018, October 15, 2018

[RFA-MH-18-704 \(R61/R33\)](#) – clinical trial required

[RFA-MH-18-705 \(R33\)](#) – clinical trial required

#### **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

These FOAs support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach.

**Application Due Dates:** June 15, 2018, October 15, 2018

[RFA-MH-18-707 \(R01\)](#) – clinical trial required

#### **Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders**

This FOA supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention.

**Application Due Dates:** June 15, 2018, October 15, 2018

[RFA-CA-17-017 \(R01\)](#); [RFA-CA-17-018 \(R21\)](#)

#### **Research Answers to NCI's Provocative Questions**

The purpose of these FOAs are to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. Each research project must be focused on addressing one particular research problem defined by one specific PQ selected from the list found in the FOAs.

**Application Due Dates:** June 28, 2018; October 30, 2018

[RFA-OD-18-002 \(R01\)](#); [RFA-OD-18-003 \(R21\)](#); [RFA-OD-18-001 \(R03\)](#) – clinical trial optional

#### **Tobacco Regulatory Science**

These FOAs invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. **Application Due Dates:** July 17, 2018, February 13, 2019

[RFA-HL-17-022 \(R21\)](#)

#### **Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research**

This FOA will support meritorious exploratory research relevant to the [NHLBI mission](#) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals. **Application Due Dates:** October 17, 2018; February 15, 2019; October 17, 2019

[RFA-DA-18-020 \(UG3/UH3\)](#) – clinical trial optional

#### **NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders**

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum.

**Application Due Dates:** July 25, 2018; July 25, 2019, July 25, 2020

[RFA-DA-18-019 \(DP1\)](#) – clinical trial optional

#### **NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research**

This Program supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities

**Application Receipt Dates:** August 14, 2018; August 14, 2019; August 14, 2020

[RFA-DA-19-002 \(UG3/UH3\)](#) – clinical trials optional

#### **Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose**

Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose.

**Application Due Dates:** Applications will be accepted on a rolling basis **Expiration Date:** January 2, 2020

## NIH Funding Opportunities: Program Announcement with Set-Aside Funds (PAS)

[PAS-18-698 \(R01\)](#) – clinical trial optional

### **High Priority HIV/AIDS Research within the Mission of the NIDDK**

This FOA seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research. These priorities are described in [NOT-OD-15-137](#): NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding. Application Due Dates: Standard dates apply; **Expiration Date**: January 8, 2021

## NIH Funding Opportunities: Program Announcement Reviewed by an Institute (PAR)

[PAR-18-681 \(R01\)](#) – clinical trial optional

### **Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control**

This FOA encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum.

**Application Due Dates**: April 11, 2018; October 10, 2018; April 11, 2019, October 11, 2019

[PAR-18-661 \(U01\)](#) – clinical trial not allowed

### **Pathway and Target Identification for Alzhiemers Disease Related Dementias (ADRDs)**

The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology. **Application Due Date**: April 16, 2018

[PAR-18-692 \(K18\)](#) – clinical trial required

### **Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences**

This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. **Application Due Dates**: May 1, 2018 and April 13, 2019

[PAR-18-683 \(R61/R33\)](#); [PAR-18-684 \(R33\)](#) – clinical trial required

### **NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics**

The objective of these FOAs is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial.

**Application Due Dates**: June 4, 2018; October 2, 2018; June 4, 2019; October 2, 2019; June 4, 2020; October 2, 2020

[PAR-18-675 \(R01\)](#); [PAR-18-674 \(R21\)](#) – clinical trial optional

### **U.S. Tobacco Control Policies to Reduce Health Disparities**

These FOAs support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. Applicants submitting applications related to health economics are encouraged to consult [NOT-OD-16-025](#) to ensure that the research projects align with NIH mission priorities in health economics research.

**Application Due Dates**: June 13, 2018; October 11, 2018; June 13, 2019; October 11, 2019; June 15, 2020

[PAR-18-704 \(R01\)](#); [PAR-18-703 \(R21\)](#) – clinical trial not allowed

### **Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention**

These FOAs encourage research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks.

**Application Due Date**: July 11, 2018

[PAR-18-654 \(R01\)](#); [PAR-18-655 \(R21\)](#) – clinical trials not allowed

**Basic Research in Cancer Health Disparities**

These FOAs encourage grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. Funding will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. **Application Due Dates:**

June 19, 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020

[PAR-18-694 \(R24\)](#) – clinical trial optional

**Interdisciplinary Research Teams to Investigate Reciprocal Basic Behavioral and Social Linkages Between Sleep and Stress**

This initiative supports the development of research teams to understand how basic individual, social, biological, and environmental factors interact in a dynamic relationship between sleep patterns and psychosocial stress to influence health, wellness, disease, and/or treatment adherence. **Application Due Date:** October 29, 2018

[PAR-18-659 \(R21/R33\)](#) – clinical trials not allowed

**Mechanisms of Alcohol Tolerance**

The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase.

**Application Due Dates:** Standard dates apply; **Expiration Date:** May 8, 2021

[PAR-18-689 \(R01\)](#); [PAR-18-691 \(R21\)](#); [PAR-18-690 \(R03\)](#) – clinical trial optional

**Innovative Therapies and Tools for Screenable Disorders**

These FOAs encourage research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment.

**Application Due Dates:** Standard dates apply; **Expiration Date:** May 8, 2021

[PAR-18-706 \(R01\)](#) – clinical trial not allowed

**Selective Cell and Network Vulnerability in Aging and Alzheimers Disease**

The goal of this FOA is to define and characterize neural cell populations, neural circuits, and brain networks and regions that are vulnerable to brain aging and Alzheimer's disease (AD). Understanding mechanisms underlying selective vulnerability from cells to networks in AD is critical to fully define the disease process and to develop effective therapies. **Application Due Dates:** Standard dates apply; **Expiration Date:** November 6, 2019

## NIH Funding Opportunities: Program Announcements (PA)

The following program announcements have standard due dates, unless otherwise noted.

[PA-18-651 \(R01\)](#); [PA-18-652 \(R21\)](#); [PA-18-653 \(R34\)](#) – clinical trial optional

**Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults**

**Expiration Date:** January 8, 2021

[PA-18-660 \(R01\)](#) – clinical trial not allowed

**Genetics of Alcohol Sensitivity and Tolerance**

**Expiration Date:** May 8, 2021

[PA-18-677 \(R01\)](#); [PA-18-678 \(R21\)](#) – clinical trial not allowed

**Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility**

**Expiration Date:** May 8, 2021

[PA-18-705 \(R43/R44\)](#) – clinical trial not allowed

**SBIR Technology Transfer**

**Expiration Date:** April 6, 2021

[PA-18-699 \(R01\)](#); [PA-18-695 \(R21\)](#) – clinical trial not allowed

**Basic and Translational Oral Health Research Related to HIV/AIDS**

**Expiration Date:** January 8, 2021



## PARENT ANNOUNCEMENTS

### Training Grants

#### [PA-18-666 \(F31\)](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research**  
Expiration Date: January 8, 2021

#### [PA-18-668 \(F30\)](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs**  
Expiration Date: January 8, 2021

#### [PA-18-670 \(F32\)](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship**  
Expiration Date: January 8, 2021

#### [PA-18-671 \(F31\)](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship**  
Expiration Date: January 8, 2021

#### [PA-18-672 \(F33\)](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship**  
Expiration Date: January 8, 2021

## Funding Opportunities: Foundations

### Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is inviting proposals for the latest round of [Grand Challenges Explorations](#). Applicants can be at any experience level; in any discipline; and from any organization, including colleges and universities, government laboratories, research institutions, non-profit organizations, and for-profit companies. Initial grants will be US \$100,000 each, and projects showing promise will have the opportunity to receive additional funding of up to US \$1 million. Applications will be accepted on the following topics:

- Affordable, Accessible, and Appealing: The Next Generation of Nutrition
- Innovations in Immunization Data Management, Use, and Improved Process Efficiency
- Tools and Technologies for Broad-Scale Disease Surveillance of Crop Plants in Low-Income Countries

**Application Due Date:** May 2, 2018

### Robert Wood Johnson Foundation

**Evidence for Action (E4A): Investigator-Initiated Research to Build a Culture of Health** supports rigorously designed quantitative, qualitative, and mixed methods research that yields convincing findings regarding the population health, well-being, and equity impacts of specific policies, programs and partnerships. The Foundation is especially interested in research examining the health impacts of programmatic or policy interventions that address factors outside the domain of health care services or public health practice. Awards are up to 3 years; there is no explicit range of award amounts, applicants should request the amount of funding needed to complete the project.

**Application Due Date:** Applications are accepted on a rolling basis

**Evidence for Action: Matching Service** is a program whose goal is to catalyze research partnerships that result in rigorously designed studies that could be funded by Evidence for Action (E4A), another Robert Wood Johnson Foundation program, or other funding source. E4A will support a “matching team” overseen by a grantee organization. The grantee’s primary role will be to link organizations working in and with communities with strong research partners to rigorously evaluate the health impacts of program or policy interventions. Organizations working in and with communities may include health care providers, nonprofits, community-based organizations, and social service or government agencies, which have the infrastructure to implement initiatives but limited research capacity for scientifically rigorous evaluation of their impact. **Application Due Date:** April 26, 2018

*“I have noticed even people who claim everything is predestined, and that we can do nothing to change it, look before they cross the road.”*

Stephen Hawking (1942—2018)  
theoretical physicist